CompletedPhase 1NCT03925935
Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
Studying Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Angiocrine Bioscience
- Principal Investigator
- Paul Finnegan, MD, MDAngiocrine Bioscience
- Intervention
- AB-205(biological)
- Enrollment
- 42 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2021
Study locations (9)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- UC Davis Comprehensive Cancer Center, Sacramento, California, United States
- UC San Diego Moores Cancer Center, San Diego, California, United States
- The University of California San Francisco, San Francisco, California, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- MD Anderson, Houston, Texas, United States
Collaborators
California Institute for Regenerative Medicine (CIRM)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03925935 on ClinicalTrials.govOther trials for Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT07283822Amping up With PemJAKSeda S. Tolu
- RECRUITINGNANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT06854003BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaChristine Ryan
- ACTIVE NOT RECRUITINGPHASE1NCT06622226A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06522932PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T TherapyMichael Randall
- RECRUITINGPHASE1NCT06420089CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Vittoria Biotherapeutics